Purified anti-mouse IFN-γ Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

E. coli-expressed, recombinant mouse IFN-γ

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography.

Concentration

0.5 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C.

Application

ELISA Capture - Quality tested
CyTOF® - Verified
IHC, WB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 0.5-2.0 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IFN-γ recombinant protein ranging from 2000 to 15 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA^1-4,11,14 or ELISPOT⁵ Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry^7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization^1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections^6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)

1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
7. Ferrick D, et al. 1995. Nature 373:255. (FC)
8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)

Product Citations

1. Zhang S, et al. 2017. Nature.. 10.1038/nature24283. PubMed
2. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
3. Lin F, et al. 2019. Sci Adv. 5:eaax1608. PubMed
4. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
5. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
6. Yan J, et al. 2020. Cancer Discov. 10:124. PubMed
7. Doll JR, et al. 2020. PLoS Pathog. 16:e1008296. PubMed
8. Harel M, et al. 2020. J Immunol. 205:1167. PubMed
9. Yu H, et al. 2020. Front Immunol. 11:1773. PubMed
10. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
11. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
12. Liu T, et al. 2023. Cardiovasc Res. 119:1046. PubMed
13. Bahreyni A, et al. 2023. Biomed Pharmacother. 163:114789. PubMed
14. Bahreyni A, et al. 2023. BMC Med. 21:193. PubMed
15. Guo R, et al. 2020. Cell Res. 30:21. PubMed
16. Asthagiri Arunkumar G, et al. 2019. Vaccine. 37:5567. PubMed
17. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
18. Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed
19. Waickman AT, et al. 2017. Cytokine. 99:266. PubMed
20. Xu L, et al. 2017. Int J Biol Macromol. . 10.1016/j.ijbiomac.2017.07.090. PubMed
21. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
22. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
23. Yang J, et al. 2020. Front Immunol. 10:3048. PubMed
24. de Souza RG, et al. 2021. Am J Pathol. 191:294. PubMed
25. Haque M, et al. 2021. Viruses. 13:. PubMed
26. Dienz O, et al. 2020. J Immunol. 204:1521. PubMed
27. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
28. Matthias J, et al. 2020. J Clin Invest. 130:4587. PubMed
29. Flores–Santibáñez F, et al. 2018. Front Immunol. 0.520138889. PubMed
30. Knuschke T, et al. 2018. Front Immunol. 0.801388889. PubMed
31. Schafflick D, et al. 2020. Nat Commun. 247:11. PubMed
32. Willimsky G, et al. 2021. Elife. 10:. PubMed
33. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
34. Kaisar MMM, et al. 2018. PLoS Biol. 16:e2005504. PubMed
35. Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed
36. Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed
37. Singh PP, et al. 2021. Ocul Surf. 21:271. PubMed
38. Hua J, et al. 2018. Sci Rep. 5.235416667. PubMed
39. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
40. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
41. Kamdar K, et al. 2018. J Immunol. 201:230. PubMed
42. Overacre-Delgoffe AE, et al. 2017. Cell. 169:1130. PubMed
43. Juneja VR, et al. 2017. J Exp Med. 214:895. PubMed
44. Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed
45. Tan Z, et al. 2020. Mol Ther Oncolytics. 16:302. PubMed
46. Hsiao CC, et al. 2021. Cells. 10:. PubMed
47. Bittner-Eddy PD, et al. 2020. Front Immunol. 11:677. PubMed
48. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
49. Enders M, et al. 2020. J Immunol. 204:87. PubMed
50. Chung YM, et al. 2021. J Immunother Cancer. 9:. PubMed
51. Opejin A, et al. 2020. Cell Reports. 33(8):108424. PubMed
52. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
53. Riggan L, et al. 2020. Cell Rep. 31:107651. PubMed
54. Huang L, et al. 2021. Dev Neurobiol. 81:736. PubMed
55. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
56. Tonkin D, et al. 2008. J Immunol. 181:4516. PubMed
57. Daley D, et al. 2017. Nat Med. 23:556. PubMed
58. Yates K, et al. 2018. Proc Natl Acad Sci U S A. 115:2162. PubMed
59. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
60. Tan CL, et al. 2018. Immunohorizons. 0.248611111. PubMed
61. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
62. Kim SJ, et al. 2020. Cell Mol Immunol. 17:728. PubMed
63. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
64. Ranjan K, et al. 2021. J Clin Invest. 131:. PubMed
65. Van Dis E, et al. 2022. PLoS Pathog. 18:e1010721. PubMed
66. Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed
67. Kakaradov B, et al. 2017. Nat Immunol. 18:422. PubMed
68. Rosenbaum M, et al. 2019. Nat Commun. 2.05. PubMed
69. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
70. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
71. Ko S, et al. 2005. J Immunol. 175:3309. PubMed
72. Xu G, et al. 2007. J Immunol. 179:5358. PubMed
73. Dudek M, et al. 2021. Nature. 592:444. PubMed
74. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
75. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
76. Tsai MS, et al. 2021. Int J Mol Sci. 22:. PubMed
77. Sun Y, et al. 2021. Nat Commun. 12:5147. PubMed
78. Takeuchi Y, et al. 2021. Sci Rep. 11:18679. PubMed
79. Uehara H, et al. 2021. eLife. 10:00. PubMed
80. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
81. Mittal D, et al. 2017. Cancer Immunol Res. 5:1098. PubMed
82. Wagner AK, et al. 2017. Nat Commun. 8:15627. PubMed
83. Kaushik DK, et al. 2019. J Clin Invest. 130. PubMed
84. García-Lozano A, et al. 2018. Front Microbiol. 9:1275. PubMed
85. Lee B, et al. 2019. Front Immunol. 0.561805556. PubMed
86. Haring J, et al. 2008. J Immunol. 180:2855. PubMed
87. Lee JK, et al. 2021. Cell Mol Immunol. 18:1395. PubMed
88. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
89. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
90. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
91. Jordan J, et al. 2008. Infect Immun. 76:3717. PubMed
92. Bordoloi D, et al. 2021. Genes Cancer. 12:51. PubMed
93. Sutiwisesak R, et al. 2020. PLoS Pathog. 16:e1009000. PubMed
94. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
95. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed

RRID

AB_315395 (BioLegend Cat. No. 505801)
AB_315395 (BioLegend Cat. No. 505802)

Antigen Details

Structure

Cytokine; dimer; 40-80 kD (Mammalian)

Bioactivity

Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs

Cell Sources

CD8⁺ and CD4⁺ T cells, NK cells

Cell Targets

T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts

Receptors

IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)

Cell Type

Tregs

Biology Area

Cell Biology, Immunology, Neuroinflammation, Neuroscience

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation

Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone

Gene ID

15978 View all products for this Gene ID

UniProt

View information about IFN-gamma on UniProt.org

Related Protocols

• Active Protocols: Sandwich ELISA - Video

Other Formats